Roche Escalates High-Stakes Pharma Battle, Challenges Natco's Generic Risdiplam in Supreme Court

NEW DELHI – The long-running and closely watched patent dispute between Swiss pharmaceutical giant F. Hoffmann-La Roche AG and Indian generic drug manufacturer Natco Pharma has reached the nation's apex court. Roche has filed a plea with the Supreme Court of India, challenging a Delhi High Court order that cleared the path for Natco to manufacture and market its generic version of Risdiplam, a critical drug for treating the rare and debilitating genetic disorder, Spinal Muscular Atrophy (SMA).

The matter was urgently mentioned before the Chief Justice of India, who agreed to list the case for hearing, signaling the gravity of the legal questions at stake. The Supreme Court's intervention is poised to have profound implications for India's patent enforcement landscape, particularly the delicate balance between protecting intellectual property rights of innovators and ensuring public access to affordable, life-saving medicines.

The appeal follows a significant setback for Roche at the Delhi High Court. On October 9, a Division Bench comprising Justice C. Hari Shankar and Justice Ajay Digpaul dismissed Roche's appeal, affirming a Single Judge's earlier refusal to grant an interim injunction against Natco. This decision effectively allows Natco to continue its "at-risk" launch of the generic drug while the primary patent infringement suit proceeds.

The Core of the Dispute: Patent Validity and Prior Art

The legal battle originates from Roche's claim that Natco's generic product directly infringes upon its Indian Patent No. IN 384397 (IN'397), which covers compounds for treating SMA and is valid until 2035. In response to Roche's infringement suit, Natco deployed a formidable defense, not merely denying infringement but challenging the very validity of Roche's patent.

Invoking the statutory defense available under Section 107(1) of the Patents Act, 1970, Natco argued that Roche's patent was vulnerable to revocation on grounds of lacking novelty (Section 64(1)(e)) and, more pivotally, being obvious to a person skilled in the art (Section 64(1)(f)). This defense hinges on the assertion that the patented invention, Risdiplam, did not involve a sufficient "inventive step" over existing knowledge, or "prior art."

The Delhi High Court's decisions, both at the Single Judge and Division Bench levels, were heavily influenced by Natco's "credible challenge" to the patent's validity. The courts found prima facie merit in Natco's argument that Risdiplam was obvious in light of a previously disclosed compound. The Division Bench was unequivocal in its finding, stating it found “no reason to interfere with the findings of the learned Single Judge that Risdiplam is vulnerable to invalidity in terms of Section 64(1)(f) of the Patents Act, as being obvious vis-à-vis prior art in the form of the claimed Compound 809 in WO'916/US'955.”

This reference to "Compound 809" as prior art formed the crux of the technical argument, convincing the High Court that Natco had raised a substantial question about the patent's inventive step, thereby weakening Roche's case for an interim injunction.

The High Court's Legal Reasoning: Wander v. Antox and Public Interest

In declining to interfere with the Single Judge's order, the Division Bench leaned on the well-established legal precedent set in Wander Ltd. v. Antox India P. Ltd. This principle sets a high threshold for an appellate court to overturn a lower court's discretionary order, such as the grant or refusal of an interim injunction. The appellate court's role is not to substitute its own discretion but to determine if the lower court's decision was arbitrary, perverse, or ignored settled principles of law. The Bench concluded that “no case for interference with the said decision, within the parameters of Wander , can be said to have been made out.”

Beyond the technical patent arguments, the element of public interest loomed large in the High Court's considerations. The court noted the critical nature of Risdiplam as a life-saving therapy for SMA patients and the significant price disparity between Roche's product and Natco's generic version. Following the initial court victory, Natco announced the immediate launch of its generic Risdiplam at an MRP of ₹15,900, a fraction of the cost of the innovator drug, and committed to a patient access program.

The Single Judge's earlier order had explicitly emphasized the importance of "keeping the life-saving therapy affordable and accessible," highlighting that the high price of the patented drug restricted access for the majority of patients in India. This balancing act—weighing the patent holder's monopoly against the compelling public interest in accessing essential medicines—is a recurring theme in Indian pharmaceutical litigation and will likely be a key consideration for the Supreme Court.

Implications for the Pharmaceutical and Legal Sectors

The Supreme Court's decision to hear the matter has sent ripples through the market, with Natco Pharma's shares experiencing a 3.5% drop following the news, reflecting investor uncertainty. The outcome of this case will be scrutinized for its potential to set new precedents in several key areas of intellectual property law:

• The "Credible Challenge" Defense: The case will test the strength of the "credible challenge" or "Gillette" defense, where a defendant in an infringement suit argues the patent's invalidity. A Supreme Court ruling could clarify the evidentiary standard required for a defendant to establish a prima facie case of invalidity sufficient to prevent an interim injunction.

• Standard for Interim Injunctions: The Court may revisit the tripartite test for granting interim injunctions (prima facie case, balance of convenience, and irreparable harm) in the specific context of pharmaceutical patents where a public interest component is strongly present.

• Obviousness and Prior Art: The technical analysis of "obviousness" vis-à-vis prior art is central to the dispute. The Supreme Court's examination of the High Court's findings on Compound 809 could provide further guidance on how inventive step is assessed in complex chemical and pharmaceutical patents.

• At-Risk Launches: The case exemplifies an "at-risk" launch, where a generic company enters the market before the final adjudication of a patent's validity. The Supreme Court's stance could influence the risk calculus for other generic manufacturers planning similar strategies.

As the legal teams for Roche and Natco prepare their arguments for the Supreme Court, the broader legal and healthcare communities await a decision that could redefine the contours of patent protection and drug accessibility in India for years to come.